nisolone therapy lasted for an average of 3.6 months and a complete long-lasting response was achieved in 35 of 42 AIU patients (83.3%). The follow-up period was at least 36 months (3 years) for each AIU patient; the longest follow-up time was 139 months (11.5 years). None of the patients reported any considerable side effects. Conclusion: Based on our results, we suggest that the use of this treatment could be an alternative for the treatment of AIU. Our present results also highlight the need for other therapies in a small percentage of AIU patients. Our results suggest that AIU represents a transient autoimmunity that can be successfully treated with low-dose steroid therapy administered for a few months.
Introduction
Chronic spontaneous urticaria (CSU) has an estimated prevalence of 0.5-1.8%. CSU is defined as symptoms of urticaria usually occurring daily and persisting for 6 weeks or more. In some patients, dermographism or urticaria factitia can also be detected. Patients with urticar-
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Abstract Background: Chronic spontaneous urticaria (CSU) is defined as symptoms of urticaria persisting for 6 weeks or more without obvious cause. Autologous serum skin test (ASST) positivity in patients with CSU is considered to be associated with autoimmune urticaria (AIU). Methods: In this retrospective study we retrieved the medical records of 1,073 urticaria patients seen at the Department of Dermatology and Allergology of Szeged University between January 2005 and February 2014. Forty-two patients (36 female and 6 male) met the study criteria by having CSU and giving positive results in the ASST. Our aim was to assess the clinical efficacy and safety of low-dose oral prednisolone therapy administered to patients with antihistamine-refractory ASST-positive CSU for a few months. Patients were given an initial dose (40 mg/day) of prednisolone until the complete resolution of the symptoms, usually 7-10 days, and then the dose was gradually decreased, as in other autoimmune diseases. Results: Pred-ia may experience concomitant angioedema and intensive itching. Characteristic wheals last for no more than 24 h. The term "chronic spontaneous urticaria" is relatively new, as chronic urticaria has recently been divided into two main groups: "chronic spontaneous urticaria" (CSU) and "chronic inducible urticaria," the latter including the previously termed "physical urticaria" [1, 2] . A concomitant autoimmune mechanism can be detected in 30-50% of CSU patients. Autoimmune urticaria (AIU) is not a well-defined condition, but based on some evidence it is accepted that some CSU patients have anti-IgG antibodies against the alpha chain of the high-affinity IgE receptor (Fc Ɛ RI) on mast cells and basophil granulocytes and/or against IgE [3] [4] [5] [6] [7] .
The autologous serum skin test (ASST), an in vivo cutaneous test, is based on intradermal injections of small quantities of autologous serum. It was first described in 1986 as a diagnostic tool for chronic idiopathic urticaria CIU [8] [9] [10] . ASST has been widely adopted internationally as a clinical screening method to assess autoreactivity in CSU. In the latest EAACI/GA 2 LEN/EDF/WAO (2014) guideline, nonsedating H 1 antihistamines at the conventional dose is recommended as first-line therapy for CSU, and as second-line therapy it is advised to raise the dose up to 4 times in nonresponding urticaria patients [1, 11] . If patients are unresponsive to both first-and second-line treatment, the administration of other systemic therapies could be initiated, including azathioprine, leukotriene antagonists, cyclosporine A and/or mycophenolate mofetil, dapsone, TNF-α inhibitors, plasmapheresis, intravenous immunoglobulin, and omalizumab.
In this latest guideline systemic steroid therapy is only recommended for a few days, when patients experience a severe flare. Flares are frequent among CIU patients, therefore these patients often take steroids regularly on an on-off basis, without long-lasting therapeutic effect. Kaplan [2, 12] recommended a longer course of prednisolone therapy for chronic idiopathic urticaria (CIU) patients who were unresponsive to antihistamines. Kaplan treated patients with 40 mg/day prednisolone for the first 3 days and then decreased the prednisolone dosage by 5 mg/day gradually, according to the symptoms; when the dosage was down to 25 mg/day, it was further decreased by 5 mg on alternate days. The steroid then was slowly withdrawn by decreasing the dose by 5 mg every 2-3 weeks. In his experience a 3-month course of such prednisolone therapy was sufficient for healing the patients. Given the autoimmune nature of ASST-positive CSU, we followed the recommendation of Kaplan and used a prolonged course of low-dose oral prednisolone therapy in AIU patients.
The aim of this retrospective study was to assess the efficacy and safety of this therapeutic approach in patients with ASST-positive CSU. 
Methods
For further details, see the supplementary material (see www. karger.com/doi/10.1159/000484085 for all online suppl. material) [1] (Fig. 1 ).
Results
Our 42 AIU patients had symptoms (urticaria, itching, and/or angioedema) for many years and about 1/3 of them have experienced factitious urticaria. Thirty-six of the patients included were women (85.71%) and 6 were men (14.28%). The mean age at diagnosis was 54 years (26-87 years; median: 56.51 years). In 11 of the 42 patients, anti-thyroglobulin and anti-thyroid peroxidase antibodies were also detected. AIU was associated with urticaria factitia in 12 of the 42 patients. All concomitant diseases of the patients are listed in Table 1 . The majority of the patients had had treatment for various types of infections (otorhinolaryngological, dental, urological, gynecological, and Helicobacter pylori infection) during the previous course of their disease.
Out of the 42 patients, 35 (83.3%) became free of symptoms after the initiation of steroid treatment and their therapy lasted for an average of 3.6 months (1-13 months; Fig. 2 ). The absolute mean daily dosage was 22.06 mg/day for the responding 35 patients (for patients who took the steroid for less than 4 months it was 0.34 mg/kg and for those who needed longer treatment it was 0.20 mg/kg). The mean daily dosage for the 35 patients was 0.32 mg/kg. None of these 35 patients relapsed during follow-up (Fig. 2) ; thus among these patients a complete long-lasting clinical remission was achieved. Among the 7 nonresponder patients, some partially responded to the therapy, but they never became completely symptom free. We detected no difference in terms of concomitant diseases between the two groups, responders versus nonresponders ( Table 1 ). The follow-up of the patients after the end of the prednisolone therapy covered a period from 3 to 11.5 years (Fig. 2) ; In this group of patients we had no serious adverse events; however, 4 patients experienced transitional hair loss and 3 patients gained weight [13] .
Discussion
Patients with CSU may suffer from stigmatization due to their skin lesions (wheals, excoriations due to itching, and angioedema) and the disease often causes considerable aesthetic and psychological problems. Various therapeutic modalities have been attempted with the aim of improving symptoms of CSU with differing degrees of success, e.g., first-and second-generation antihistamines, leukotriene antagonists, corticosteroids, hydroxychloroquine, dapsone, colchicine, sulfasalazine, cyclosporine, and omalizumab [1] . In everyday practice one of the most common drugs used to treat severe CSU are corticosteroids, although current guidelines do not recommend steroid therapy for prolonged periods of time since its 422 side effects could be considerable (hypertension, osteoporosis, cutaneous striae, obesity, cataract, diabetes, etc.). In 1986 Grattan et al. [8] identified AIU among patients with CSU, termed at the time CIU. Many case reports described the rapid efficacy of steroid therapy in AIU, but no complete and long-lasting response has been reported on prednisolone treatment. The EAACI/GA 2 LEN/EDF/ WAO guidelines have discouraged the long-term use of oral corticosteroids in chronic urticaria, although evidence for this recommendation was lacking [1] .
Systemic corticosteroids can exert influence on multiple levels: they suppress antibody formation, have a strong anti-inflammatory effect, and decrease the production of histamine-releasing factors. AIU is characterized by IgG antibodies against the alpha chain of the highaffinity IgE receptor (Fc Ɛ RI) on mast cells and basophil granulocytes and/or by antibodies directed against IgE antibodies. These antibodies play a role in mast cell and basophil activation and in the release of both preformed and newly generated mediators (chemokines, cytokines, histamine, serotonin, and leukotrienes) [5, 7, 11, 14] . The "gold standard" in vitro methods in AIU detect seruminduced histamine release in basophils (HR assay) and CD63 expression on basophils and mast cells [15] [16] [17] . Laboratory tests with high specificity and sensitivity are required for screening patients to detect circulating functional autoantibodies and thereby unequivocally diagnosing AIU among CSU patients. Recently, Lee et al. [18] developed a rapid immunodot method with high specificity to detect autoantibodies against the Fc Ɛ RIα chain in the sera of CSU patients. Unfortunately, these tests are not available yet in everyday clinical practice. Presently, the ASST is used in clinical practice to detect AIU. In AIU, the incidence of anti-thyroid antibodies is higher, and patients should be screened for anti-thyroid peroxidase and anti-thyroglobulin antibodies [19] .
Because it has been demonstrated that ASST with undiluted serum could result in nonspecific positive reactions, Husz et al. [20] suggested the use of 1: 10 and 1: 100 serum dilutions in order to avoid nonspecific test reac- tions. In a follow-up study the same workgroup compared the dilution ASST with the CD63 expression test and concluded that dilution did not improve the specificity of the test. However, the severity of AIU correlated well with positive reactions at diluted serum, and therefore it was suggested that using different dilutions of the serum in ASST might serve as a useful indicator of disease severity [21] . The detected autoreactivity, however, does not directly prove the presence of autoantibodies. Szegedi and colleagues [22] suggested complementing the ASST results with characteristic clinical signs to improve the diagnosis of AIU. The sensitivity (88%) and specificity (77%) of ASST complemented with simultaneous clinical symptoms (wheals 6-7 times a week, angioedema and anti-thyroid antibodies) considerably increased the sensitivity (up to 94%) and specificity (up to 86%) of this test.
To our knowledge this is the first report on the use of this few-months-long low-dose oral corticosteroid therapy in a larger AIU study group. The prolonged (average 3.6 months) immunosuppressive therapy proved to be safe and effective in improving the symptoms of patients with positive ASST. Only a few patients experienced light transitional adverse effects during treatment. The circulating autoantibodies responsible for the autoreactive mechanisms in AIU may not be long-lasting and a prolonged oral prednisolone therapy seems to restore the normal balance of the immune system. Although spontaneous remission is possible, these patients suffer from their symptoms and they need treatment. Based on our results, we consider that prolonged administration of low-dose oral corticosteroids can be a valuable therapeutic alternative in patients with therapy-resistant AIU urticaria. However, our results have also highlighted the need for other therapeutic approaches (e.g., omalizumab) in a small percentage of AIU patients.
Key Message
Low-dose oral corticosteroid therapy administered for a few months can treat autoimmune urticaria patients.
